Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more
Diagnos Laboratorium Utama PT Tbk (DGNS) - Total Assets
Latest total assets as of June 2025: Rp304.08 Billion IDR
Based on the latest financial reports, Diagnos Laboratorium Utama PT Tbk (DGNS) holds total assets worth Rp304.08 Billion IDR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Diagnos Laboratorium Utama PT Tbk - Total Assets Trend (2017–2024)
This chart illustrates how Diagnos Laboratorium Utama PT Tbk’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Diagnos Laboratorium Utama PT Tbk - Asset Composition Analysis
Current Asset Composition (December 2024)
Diagnos Laboratorium Utama PT Tbk's total assets of Rp304.08 Billion consist of 26.2% current assets and 73.8% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 1.4% |
| Accounts Receivable | Rp48.89 Billion | 16.3% |
| Inventory | Rp5.04 Billion | 1.7% |
| Property, Plant & Equipment | Rp202.43 Billion | 67.5% |
| Intangible Assets | Rp1.35 Billion | 0.5% |
| Goodwill | Rp0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Diagnos Laboratorium Utama PT Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Diagnos Laboratorium Utama PT Tbk's current assets represent 26.2% of total assets in 2024, a decrease from 84.9% in 2017.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2024, down from 15.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 67.5% of total assets.
Diagnos Laboratorium Utama PT Tbk Competitors by Total Assets
Key competitors of Diagnos Laboratorium Utama PT Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Diagnos Laboratorium Utama PT Tbk - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Diagnos Laboratorium Utama PT Tbk generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Diagnos Laboratorium Utama PT Tbk generates $ 0.25 in net profit.
Diagnos Laboratorium Utama PT Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.74 | 3.37 | 3.44 |
| Quick Ratio | 3.55 | 3.24 | 3.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp61.89 Billion | Rp 67.23 Billion | Rp 74.54 Billion |
Diagnos Laboratorium Utama PT Tbk - Advanced Valuation Insights
This section examines the relationship between Diagnos Laboratorium Utama PT Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.5% |
| Total Assets | Rp300.02 Billion |
| Market Capitalization | $4.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Diagnos Laboratorium Utama PT Tbk's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Diagnos Laboratorium Utama PT Tbk's assets grew by 10.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Diagnos Laboratorium Utama PT Tbk (2017–2024)
The table below shows the annual total assets of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp300.02 Billion | +10.52% |
| 2023-12-31 | Rp271.48 Billion | +13.14% |
| 2022-12-31 | Rp239.94 Billion | -0.85% |
| 2021-12-31 | Rp241.98 Billion | +82.53% |
| 2020-12-31 | Rp132.57 Billion | +123.86% |
| 2019-12-31 | Rp59.22 Billion | +142.33% |
| 2018-12-31 | Rp24.44 Billion | +187.91% |
| 2017-12-31 | Rp8.49 Billion | -- |